Xhance is a new nasal spray to be available April 2018. Xhance is indicated for the the treatment of nasal polyps in patients 18 years or older. The active ingredient in Xhance is fluticasone propionate 93 mcg. If that sounds familiar, fluticasone propionate is the active ingredient in Flonase. What is different from Xhance from […]
PR022 for Atopic Dermatitis (Eczema)
PR022 is a new topical gel being studied for the treatment of atopic dermatitis. It is entering Phase 2 trials and it is being manufactured by Realm Therapeutics. Data is supposed to come out in the 3rd quarter of 2018. PR022 consists of hypochlorous acid (HOCL). HOCL is an ideal wound care agent with powerful […]
AllergyLosAngeles.com named top Allergy Blog Again
Our website was named a top allergy blog by feedspot.com and our blog came in at #8 this year. It is a great honor to be named one of the top allergy blogs in the world. Many other blog sites have teams of writers who write for them, but we have just one blogger, Dr. […]
Dupilumab for Nasal Polyps
Since the release of dupilumab for atopic dermatitis, studies are currently underway to investigate dupilumab for nasal polyps, asthma and a host of other conditions. Dupilumab is a human monoclonal antibody against interleukin 4 and 13. A study published in JAMA titled “Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis […]
Pet Allergies and Asthma
Pet allergies and asthma are big problems in this country. Pet allergy in the home, notably sensitization to cats and dogs, is a strong predictor of the development of childhood asthma. More cases of asthma could be attributed to cat allergen than any other sensitization. Other investigations have shown that there is a protective effect […]
Risk Factors for Eosinophilic Esophagitis
With the rise of eosinophilic esophagitis being diagnosed in the United States, there likely is a contributing factor. This is evidenced from twin studies that show stronger disease concordance in twins compared with non twin siblings, suggesting that early-life factors contribute. Studies have shown that environmental factors account for nearly 85% of the disease cause. […]
Nucala (mepolizumab) vs. Cinqair (reslizumab)
In a study published in The American Journal of Respiratory Critical Care Medicine, investigators compared intravenous reslizumab (Cinqair) and mepolizumab (Nucala). Both of them are used for moderate to severe persistent asthma and they both neutralize IL-5, which produces blood eosinophilia and leads to severe eosinophilic asthma. A randomized, placebo controlled trial was used to […]
AR101 a Potential Peanut Allergy Cure
AR101 is currently being studied by Aimmune Therapeutics to induce desensitization in peanut allergic subjects. The peanut treatment, AR101, passed through phase 2 trials in 2016, protecting 100% of patients who ate 443 mg of peanuts (1.5 peanuts), 90% of those who ate 1,043 mg (3 peanuts) and 60% who ate 2,043 mg (7 peanuts). A single […]
Food Diversity and Allergic Disease
Food diversity has been a hot topic in allergy since several clinical trials in high-risk children reported that early introduction of highly allergenic foods, especially peanut and egg, prevents food allergy later in life. This opened up the debate about changing recommendations about the timing of solid food introduction and the length of breast feeding […]
Allergy to Marijuana
Allergy to marijuana has been on the rise with the legalization of medical marijuana and recreational marijuana in certain states. Here in California, recreational marijuana has become legalized on January 1st, 2018. Medical marijuana has been legal for more than 20 years but now with the full legalization in California, there will be more reactions […]










